Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 144Recruiting 32Active not recruiting 32Terminated 29Withdrawn 8No longer available 2Unknown 1Not yet recruiting 1Approved for marketing 1

Sponsor Class

OTHER 17NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 1

Interventions

Injections 36Carboplatin 31Paclitaxel 24Docetaxel 24Capecitabine 24Gemcitabine 22Cisplatin 22pembrolizumab 21Oxaliplatin 21Bevacizumab 20Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11Nivolumab 8osimertinib 7Topotecan 7Leucovorin 7Dexamethasone 7toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Trastuzumab 6Doxorubicin 6Cetuximab 6130-nm albumin-bound paclitaxel 6venetoclax 5Temozolomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Prednisone × Clear all
NCT06099990 2023-10-25

Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Not yet recruiting
660 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡